The inhibition of this biological expression of DPP-4 is crucial for the anti-inflammatory activity of alogliptin
Medication alone isnt the whole story, pairing it with behavioral support and clinical oversight is where you start to see sustainable outcomes instead of short-term wins
This case report serves to highlight a critical, albeit rare, association between GLP-1 agonist therapy and the subsequent development of two distinct neurological complications: non-alcoholic Wernickes encephalopathy (NAWE) and treatment-induced neuropathy of diabetes (TIND)
Improved Metabolic Health May support reductions in visceral fat, improve lipid profiles (cholesterol/triglycerides), and contribute to better overall cardiometabolic health
GLP-1 medications can add to that tiredness, particularly during the first few weeks and after dose increases
Is Tirzepatide an effective solution for significant medical weight loss